State of the Science Evaluation:
|
|
- Osborn Powers
- 5 years ago
- Views:
Transcription
1 State of the Science Evaluation: Nonmonotonic Dose Responses as They Apply to Estrogen, Androgen, and Thyroid Pathways and EPA Testing and Assessment Procedures Photo image area measures 2 H x 6.93 W and can be masked by a collage strip of one, two or three images. The photo image area is located 3.19 from left and 3.81 from top of page. Each image used in collage should be reduced or cropped to a maximum of 2 high, stroked with a 1.5 pt white frame and positioned edge-to-edge with accompanying images. October 1, 2013 DRSG Webinar Office of Research and Development
2 Disclaimer The views expressed in this presentation are those of the author and do not represent the policy of the U.S. EPA. 1
3 2 EDCs, Low Dose and Controversy
4 The Low Dose Hypothesis Elements of the Low-Dose hypothesis EDCs have effects, especially on reproduction and development, at low doses Effects observed in exposed animals are occurring at doses similar to human exposures (i.e. at doses that are thought to be safe) Humans environmentally exposed to EDCs are affected by low doses L. Vandenberg presentation to EPA 11/06/12
5 2012 Endocrine Society Position Statement Basic scientists should be involved in evaluating the weight -of-evidence of EDC studies, as well as in the design and interpretation of studies that inform the regulation of EDCs. State-of-the-art molecular and cellular techniques, and highly sensitive model systems, need to be built into current testing, in consultation with the appropriate system experts. Testing needs to include models of developmental exposure during critical life periods when organisms may be most vulnerable to even very low -dose exposures. Endocrine principles should be incorporated into programs by the U.S. Environmental Protection Agency (EPA) and other agencies charged with evaluating chemicals for endocrine-disrupting potential. Environmental chemicals that interfere with any aspect of hormone action 4 should be presumed to cause adverse effects. Zoeller et al. 2012
6 What about NMDR? These examples, and the examples of low-dose effects in less wellstudied chemicals (Table 3), provide evidence that low-dose effects are common in EDC research and may be the default expectation for all chemicals with endocrine activity. These mechanisms are well understood, and by providing detailed biological insights at the molecular level into the etiology of NMDRCs, they strongly negate the presumption that has been central to regulatory toxicology that dose-response curves are by default monotonic. For both hormones and EDCs, NMDRCs should be the default assumption absent sufficient data to indicate otherwise. 5 Vandenberg et al. 2012
7 Nonmonotonicity and Low-dose Effects Some reports indicate that dose response curves are nonmonotonic in the lowdose range for endocrine disrupting chemicals. That is, effects observed at low doses may not be observed or may not be intensified at higher doses. If non-monotonic dose responses in human systems are demonstrated to be common for endocrine active agents, it could have significant implications for chemical assessment by regulatory agencies. 6
8 Hormones have non-linear, and often non-monotonic responses Welshons et al. 2003
9 Scope: NMDRs Rather than Low Dose Low dose effect = Biological changes that occur below NOAEL, or in the range of human exposures Non-monotonicity = Change in the sign of the slope of the dose response curve, which can occur over any range of exposure levels Max Tolerated Intake RfD LOAEL NOAEL
10 Convened international research needs workshop 1990s - Co-chaired CENR working group in mid 1990s Endocrine Disruptor Screening and Testing Advisory Committee (EDSTAC) Dose selection for studies used in risk assessment must include attention to setting a low dose Range-finding studies should include sensitive endpoints that could detect effects at low exposure concentrations 2000 EPA/NIEHS Endocrine Disruptor Low Dose Peer Review Workshop Defined Low dose a biological change, not limited to adverse effects, which occur either at human exposure levels or at doses below those routinely used in toxicity testing Key conclusions of Report Sufficient evidence for low-dose reproductive and developmental effects Some estrogens exhibit NMDRCs Implications for toxicity testing and risk assessment not resolved 2011 EPA Low Dose Workshop EPA scientists from Programs (OCSPP, ORD, OW) evaluate the science and implications for dose setting 9 Office of Research and Development EPA Has a Long History with Endocrine Disruptors
11 EPA s Statutory Authority Food Quality Protection Act (FQPA) August 3, 1996 Amended the Federal Food, Drug, and Cosmetic Act (FFDCA) Requires EPA to develop a screening program (EDSP) develop a screening program, using appropriate validated test systems and other scientifically relevant information, to determine whether certain substances may have an effect in humans that is similar to an effect produced by a naturally occurring estrogen, or other such endocrine effect as the Administrator may designate. 10 3
12 EPA Has a Long History with Endocrine Disruptors Convened international research needs workshop 1990s - Co-chaired CENR working group in mid 1990s Endocrine Disruptor Screening and Testing Advisory Committee (EDSTAC) Dose selection for studies used in risk assessment must include attention to setting a low dose Range-finding studies should include sensitive endpoints that could detect effects at low exposure concentrations 2000 EPA/NIEHS Endocrine Disruptor Low Dose Peer Review Workshop Defined Low dose a biological change, not limited to adverse effects, which occur either at human exposure levels or at doses below those routinely used in toxicity testing Key conclusions of Report Sufficient evidence for low-dose reproductive and developmental effects Some estrogens exhibit NMDRCs Implications for toxicity testing and risk assessment not resolved 2011 EPA Low Dose Workshop EPA scientists from Programs (OCSPP, ORD, OW) evaluate the science and implications for dose setting 11
13 12 Scope of 2013 EPA Review on NMDR EPA is interested in all potential NMDR impacts, but current analysis focus is on Endocrine disrupting chemicals (EDCs), Acting through the estrogen, androgen, or thyroid hormone systems Not intended to be a definitive review (or assessment) of any particular chemical Because of the limitations of the literature, document is focused on single chemical exposures This is not intended to be a policy document After peer review document will be revised After revision, document may be considered by EPA to inform our decision making
14 How EPA Developed the Review Established a cross program and cross agency working group. FDA (CDER, CFSAN), NIEHS (NTP), NIH/ NICHD But this is an EPA document Sub groups of authors worked independently More than 1000 papers reviewed for mammalian E and A 270 relevant papers evaluated in detail NMDR 28 model chemicals were selected for E and A evaluation of aquatic species with 20 papers determined to be directly relevant for the current evaluation More than 1400 papers reviewed for mammalian T 68 papers identified relevant for aquatic species T 13
15 Literature Reviews Varied approaches to searching and reviewing the literature Methodologies described for each data section e.g. for mammalian thyroid, two approaches In depth review of 3 chemicals with well characterized MOA: perchlorate (NIS symporter inhibition), propylthiourea (TPO inhibition), and polyhalogenated aromatic hydrocarbons (NR mediated hepatic enzyme induction) Systematic review and criteria for study selection 31 studies with NMDR identified (30 in vivo, 1 in vitro) Table 5 (from Appendix C.3). Reference filters used to compile the final list of published papers searched for any evidence of NMDRC for thyroid-related endpoints. All studies rated as relevant (i.e., primary publication of chemical-specific information on thyroid endpoints) were further divided into chemical-studies (see text for definitions). Total Number of References 1153 Numbers of reference that were reviews or otherwise not relevant 339 Total number of relevant references with data from chemical exposures Total Number of Chemical-Studies from relevant references 2060 Number of Non-Mammalian Chemical-Studies 229 Number of Mammalian In Vivo & All In Vitro Chemical-Studies 1831
16 Consensus Definitions for the Review Non Monotonic Dose Responses (NMDRs) measured biological effects with dose response curves that contain a point of inflection where the slope of the curve changes sign at one or more points within the tested range. Low Dose Effect a biological change occurring in the range of typical human exposures or at doses lower than those typically used in standard testing protocols. NTP (2001) Endocrine Disrupting Chemical (EDC) an exogenous substance or mixture that alters function(s) of the endocrine system and consequently causes adverse health effects in an intact organism, or its progeny, or (sub)populations. WHO (2002) Adverse Effect a measured endpoint that displays a change in morphology, physiology, growth, development, reproduction, or life span of a cell or organism, system, or population that results in an impairment of functional capacity, an impairment of the capacity to compensate for additional stress, or an increase in susceptibility to other influences. Keller et al. (2010) 15
17 Overarching Science Question Are modifications to standard test guidelines for toxicity testing used in risk assessment needed to detect and characterize nonmonotonic adverse effects for chemicals, particularly those that are mediated by effects on the endocrine system? Office of Research and Development 16
18 Key Scientific Questions 1. Do non-monotonic dose responses (NMDR) exist for chemicals and if so under what conditions do they occur? 2. Do NMDRs result in adverse effects that are not captured using our current chemical testing strategies? 3. Do NMDRs provide key information that would alter EPA s current weight of evidence conclusions and risk assessment determinations, either qualitatively or quantitatively? *Questions will be addressed as they pertain to endocrine disruption via estrogen, androgen, or thyroid pathways. Office of Research and Development 17
19 How We Developed the Review MOA guided data evaluation for identification of NMDR Focus on E, A, and T hormone systems and the relationship of disruption to adverse effect. Data evaluated based on modified Hill criteria; biological plausibility, strength, consistency, experimental design, and statistical evaluation and interpretation. Role of pharmacokinetics important in interpretation Weight of Evidence Versus strength of evidence 18
20 Example WOE 22% 16% 45% 17% Input for the REACH-review in 2013 on endocrine disrupters DANISH CENTRE ON ENDOCRINE DISRUPTERS In Vitro studies from Vandenberg et al review described as showing NMDR allocated into four groups. (N=80) 19
21 Anogenital Distance (mm) Example Statistics and Design Issues Did not re-do published statistics, but commented on applicability of tests e.g. failure to account for multiple comparisons by adjusting the p-value required for statistical significance in studies with large numbers of endpoints and dosage levels (Appendix A.1.d.1). Design 20 Limitations in experimental design, in particular the number of animals in each dose group, can lead to inaccurate interpretation of the data. Difficulty of conducting low dose studies of ubiquitous contaminants Possible Dietary Phthalate levels DEHP micrograms per kg per day
22 Document Structure 1. Introduction 2. General Biological Concepts and Statistical Considerations 3. NMDRs from in vitro Studies 4. NMDRs from in vivo Studies 4.1 Aquatic Models 4.2 Mammalian Models 4.3 Human Studies and Epidemiology 5. Conclusions 6. Bibliography 7. Appendices 21
23 22 Results and Conclusions
24 What We Found 23 NMDR from exposure to xenobiotics, do occur in biological systems but are generally not common. For the majority of chemicals, current testing identified those with potential endocrine activity. This was consistent with the goal of chemical testing to identify the potential for hazard after exposure to the xenobiotic of concern, not to identify and describe 100% of all the possible biological effects. The current testing approaches perform this function successfully and, based on the current evaluation, are highly unlikely to mischaracterize a chemical that has the potential to adversely perturb the endocrine system due to an NMDR.
25 What We Found For E and A, endpoints closest to the molecular initiating event more likely to identify point of inflection than downstream effects (including the apical adverse outcomes). e.g. in vitro assays measuring E and A receptor signaling pathways. may result from assay artifacts, cytotoxicity, or improperly controlled experimental conditions. e.g. In fathead minnows NMDRs seen in short-term time course studies -- fadrozole, prochloraz and trenbolone for gene expression and steroid endpoints. In 21-d studies, no NMDRs for apical endpoints (i.e. changes in secondary sex characteristics, growth, fertility or fecundity) 24
26 1. Do nonmonotonic dose responses (NMDRs) exist for chemicals and if so under what conditions do they occur? Yes, exposures to chemicals can result in NMDRs for specific endpoints. 25
27 1. Do nonmonotonic dose responses (NMDRs) exist for chemicals and if so under what conditions do they occur? 26 NMDRs arise from complex relationships between the dose of toxicant at its target site and the effect of interest. NMDRs are biologically plausible when at least two activities act in opposition to each other. Assays that provide data at a lower level of biological organization are more likely to identify NMDRs. Reproducibility of NMDRs is important in establishing plausibility of a response. NMDRs were more commonly identified in in vitro studies, high-dose range-finding studies, and large in vivo studies with numerous endpoints.
28 1. NMDRs were more commonly identified in in vitro studies, high-dose range studies, and shortterm studies. in vitro studies with hormone sensitive cell lines, see NMDR when two (or more) monotonic responses affect a common endpoint (e.g. cell proliferation). Frequency of effects may peak in the mid-dose range, then reverse direction at a higher dose As one effect is replaced by another (more biologically important?) effect. e.g. Decreased glans penis weight identified only at mid dose; penis malformations identified only at high dose. In studies where hundreds of endpoints are evaluated, may see NMDR (e.g. multi-generation exposures in rodents) 27
29 2. Do NMDRs capture adverse effects that are not captured using our current chemical testing strategies (i.e., false negatives)? There are certainly adverse biological changes that may occur in a nonmonotonic manner that would not be captured using current testing strategies. No testing strategy is able to assess all potential adverse effects, for all biological systems, in all tissues, for all species, in all developmental time points. (Executive Summary) Question 2 was further expanded for clarification. 28
30 2a. Are there adverse effects with NMDRs that are not being identified using the current chemical testing strategies? Assessment of the adequacy of the current testing assays concluded that a number of standardized short- and longterm assays are sensitive in detecting chemicals that interfere with the E, A, and T signaling pathways. The EDSP screening battery can detect disruption of these pathways using combined in vitro and in vivo assays in mammalian and aquatic models. Standard multigenerational guideline tests have measures that are sensitive to disruption of the E and A signaling pathways. 29
31 Response (Tumor or Nontumor Data) 2a. Are there adverse effects with NMDRs that are not being identified using the current chemical testing strategies? The objective of USEPA s chemical testing strategy is not to identify all possible adverse effects, but rather, to identify sensitive endpoints relevant to human or ecological health, providing confidence that adverse effects are not being induced at dose levels below what was determined to be a NOAEL. Dose response assessment is not the focus of screening assays Environmental Exposure Levels of Interest x (Lowest 95% Confidence Limit on Dose) (Central Estimate) Empirical Range of Observation 30 10% x 0% Linear Default x x LED 10 ED 10 x Range of Extrapolation 0 UF Nonlinear Default Dose x NOAEL x LOAEL
32 2b. Are there NMDRs for adverse effects below the no observed adverse effect levels (NOAELS) or benchmark doses (BMD) derived from the current testing strategies? Emphasis of the review was on effect of NMDR on hazard identification. But for E, A, or T we saw little evidence of NMDRs for adverse effects below the NOAELS or BMD derived from the current testing strategies. It appears that data from current testing approaches support determination of appropriate NOAELS in the low dose range of exposure, even if not all effects for every chemical are identified. Reproducible NMDRs for adverse effects occur in the high dose region of the dose response curve. 31
33 2b. Are there NMDRs for adverse effects below the no observed adverse effect levels (NOAELS) or benchmark doses (BMD) derived from the current testing strategies? Modifications to current strategies, which could lead to a more clearly defined dose response characterization and could increase the statistical power to detect low dose effects may be appropriate in specific instances. 32
34 2c. Do EPA chemical testing strategies detect relevant adverse effects for chemicals which produce NMDR for specific endpoints? Standardized short and long term assays are sensitive in detecting chemicals that interfere with the E, A, and T pathways. USEPA testing strategies are reviewed periodically to assure they are incorporating the most sensitive and biologically relevant endpoints. 33 If an objective of testing is to define the shape of the dose response curve and to identify potential NMDRs, then the three treated groups and a control group used in current guideline studies may not be sufficient for this purpose.
35 3. Do NMDRs provide key information that would alter EPA s current weight of evidence conclusions and risk assessment determinations, either qualitatively or quantitatively? NMDR (nor other dose response curves) should not be assumed to be irrelevant or spurious Data from studies in which NMDRs are identified may be biologically relevant and as such should be evaluated in context with the totality of the available scientific data in WoE conclusions and risk assessment determinations. 34
36 3. Do NMDRs provide key information that would alter EPA s current weight of evidence conclusions and risk assessment determinations, either qualitatively or quantitatively? These data should be considered and analyzed, as all data are, and factored into the WoE based on standard criteria including, but not limited to, conduct of the studies, representation of biological processes that are relevant to the evaluation, biological plausibility, and reproducibility. 35 NMDRs can have impact on both qualitative and quantitative risk assessments, but cannot be considered in isolation from other data for the chemical and biological response being considered.
37 Conclusions 1. NMDRs do occur in estrogen, androgen, and thyroid systems in ecological and mammalian studies. 2. NMDRs are not unexpected in vitro, particularly when evaluating high dose levels and/or lower-order biological endpoints in estrogen androgen or thyroid systems. 3. NMDRs are not commonly identified in estrogen, androgen, or thyroid systems in vivo and are rarely seen in apical endpoints after low-dose and/or long-term exposure. 4. The nature of a dose response will vary over time, and nonmonotonicity due to compensation may be observed. Office of Research and Development 36
38 Conclusions 5. NMDRs observed in endocrine endpoints may be biologically relevant and should be evaluated in context with the totality of the available scientific data, including epidemiologic and human studies. 6. There is currently no reproducible evidence that the early key events involved in the expression of NMDRs that are identified at low dose are predictive of adverse outcomes that may be seen in humans or wildlife populations for estrogen, androgen or thyroid endpoints 7. Therefore, current testing strategies are unlikely to mischaracterize, as a consequence of NMDR, a chemical that has the potential for adverse perturbations of the estrogen, androgen or thyroid pathways. Office of Research and Development 37
39 National Academy of Sciences, Board on Environmental Studies and Toxicology External Peer Review Charge Questions: Is the State of the Science document scientifically sound and of high quality? For this evaluation, has EPA selected studies of suitable breadth, relevance, and quality? Has EPA fairly and soundly evaluated and integrated the weight of evidence from the diversity of studies (epidemiological, mode-of-action, animal testing)? Are the assumptions valid and reasonable? Are the conclusions valid? Are there potential limitations or data gaps that would substantially impact the conclusions? Office of Research and Development 38
40 National Academy of Sciences, Board on Environmental Studies and Toxicology External Peer Review David Savitz - Chair Andrea Baccarrelli Robert Chapin Richard Corley George Daston Russ Hauser Amy Herring Andreas Kortenkam p Heather Patisaul Elizabeth Pearce Tracey Woodruff Lauren Zeise Yilian g Zhu *Comments on panel selection being accepted thru 20 May 2013 Office of Research and Development 39
41 Next Steps 40 NRC External peer review Public meeting 07/23/13 EPA input to committee as requested 2 nd and 3 rd meetings closed Report in early 2014 Public comment Through NRC Response to peer review, revision of document Final document delivered to EPA Programs for their consideration in decision making
42 Nature News Highlights 09/24/13 Journal editors trade blows over toxicology Debate flares around European regulation of bisphenol A and other endocrine disrupters Plastic bottles and many other household items contain endocrine disrupters such as bisphenol A. ISTOCK/THINKSTOCK 41
43 Info about the report To download the report To submit public comments aspx?key=
ENDOCRINE-DISRUPTING CHEMICALS
ENDOCRINE-DISRUPTING CHEMICALS INTRODUCTION Endocrine-disrupting chemicals (EDCs) are defined as: an exogenous chemical, or mixture of chemicals, that can interfere with any aspect of hormone action 1.
More informationTitle: Scientific principles for the identification of endocrine disrupting chemicals a consensus statement
Title: Scientific principles for the identification of endocrine disrupting chemicals a consensus statement Outcome of an international expert meeting organized by the German Federal Institute for Risk
More informationPotential Impacts Regarding Human Health Risk Assessment
FEDERAL INSTITUTE FOR RISK ASSESSMENT EU CONFERENCE ON ENDOCRINE DISRUPTORS Criteria for Identification and Related Impacts Potential Impacts Regarding Human Health Risk Assessment Andreas Hensel One Substance
More informationLow-dose effects, non-monotonic dose responses and endocrine disrupting chemicals
Low-dose effects, non-monotonic dose responses and endocrine disrupting chemicals J.P. Myers, Ph.D. Charlottesville, VA Carnegie Mellon University Pittsburgh, PA H. John Heinz III Center for Science, Economics
More informationEndocrine Disruptors
Endocrine Disruptors Dr. Bettina Hrdina-Zödl Institute for Plant Protection Products, Department of Toxicology Antragstellerkonferenz Vienna, 27.03.2014 www.ages.at Österreichische Agentur für Gesundheit
More informationChallenges in environmental risk assessment (ERA) for birds and mammals and link to endocrine disruption (ED) Katharina Ott, BASF SE, Crop Protection
Challenges in environmental risk assessment (ERA) for birds and mammals and link to endocrine disruption (ED) Katharina Ott, BASF SE, Crop Protection Charles River Symposium, Den Bosch, 3rd October 2017
More informationTexas Commission on Environmental Quality
Roberta L. Grant, Susan L. Santos, Mike L. Dourson, Stephanie Shirley, Neeraja K. Erraguntla, R. Jeffrey Lewis, and Nancy B. Beck Society of Toxicology, March 22-26, 2015 San Diego, CA Texas Commission
More informationDistinguishing between Mode and Mechanism of Action
Distinguishing between Mode and Mechanism of Action Michael Dourson Toxicology Excellence for Risk Assessment Center University of Cincinnati College of Medicine Conflict of Interest Statement The research
More informationContribution to the European Commission s Public Consultation on. 15 January 2015
Contribution to the European Commission s Public Consultation on Defining criteria for identifying Endocrine Disruptors in the context of the implementation of the Plant Protection Product Regulation and
More informationThe role of biokinetics in in vitro tests and the interpretation of results. Emanuela Testai
International Symposium on Alternative in vitro methods to characterize the role of EAS in hormone-targeted tissues Rome 17.12.2012 The role of biokinetics in in vitro tests and the interpretation of results
More informationWe are concerned that the focus of the document is on the estrogen, androgen, thyroid, and
Dear Members of the Guidance Document Drafting Group, The Endocrine Society appreciates the opportunity to comment on the draft guidance for identifying endocrine disruptors. Founded in 1916, the Endocrine
More informationClassification of developmentally toxic pesticides, low dose effects, mixtures perspective of the industry
Classification of developmentally toxic pesticides, low dose effects, mixtures perspective of the industry Steffen Schneider 9th Berlin Workshop on Developmental Toxicology Berlin September 13, 2018 What
More informationRisk Management Option Analysis Conclusion Document
Risk Management Option Analysis Conclusion Document Substance Name: tributyl O-acetylcitrate (ATBC) EC Number: 201-067-0 CAS Number: 77-90-7 Authority: France Date: August 2016 Version 2.1 October 2015
More informationA Testing Strategy for the Identification of mammalian Endocrine Disruptors with particular focus on steroids
A Testing Strategy for the Identification of mammalian Endocrine Disruptors with particular focus on steroids Tzutzuy Ramirez, Robert Landsiedel, Susanne Kolle, Hennicke Kamp, Bennard van Ravenzwaay EUSAAT
More informationASSESSING ENDOCRINE DISRUPTING SUBSTANCES
FEDERAL INSTITUTE FOR RISK ASSESSMENT ASSESSING ENDOCRINE DISRUPTING SUBSTANCES Handling of risk assessment under different regulations Andreas Hensel How EDs may act - sexual hormones as an example Hypothalamus
More informationWWF's RESPONSE TO THE COMMUNITY STRATEGY FOR ENDOCRINE DISRUPTORS
WWF's RESPONSE TO THE COMMUNITY STRATEGY FOR ENDOCRINE DISRUPTORS WWF WWF is the world s largest and most experienced independent conservation organisation. It has 4.7 million regular supporters and a
More informationEuropean Food Safety Authority (EFSA)
TECHNICAL REPORT APPROVED: 06 April 2017 doi:10.2903/sp.efsa.2017.en-1210 Outcome of the preliminary pesticides peer review meeting on the assessment of endocrine disrupting properties in mammalian toxicology
More informationEstablishing the Relevance of Health Hazard Data for GHS Classification: Adverse vs. Non-Adverse
Establishing the Relevance of Health Hazard Data for GHS Classification: Adverse vs. Non-Adverse Robert Roy, Ph.D. SCHC Fall Meeting Diplomate, American Board of Toxicology September 30, 2014 1 Disclaimer
More informationEndocrine Disruptors Perspective of the Endocrine Society. R. Thomas Zoeller, Ph.D. Ana M. Soto, M.D.
Endocrine Disruptors Perspective of the Endocrine Society R. Thomas Zoeller, Ph.D. Ana M. Soto, M.D. Founded in 1916 The Endocrine Society >15,000 members worldwide Basic and clinical scientists Physicians
More informationENDOCRINE-DISRUPTING CHEMICALS IN THE EUROPEAN UNION
ENDOCRINE-DISRUPTING CHEMICALS IN THE EUROPEAN UNION INTRODUCTION Endocrine-disrupting chemicals (EDCs) are chemicals, or mixtures of chemicals, that interfere with any aspect of hormone action. These
More informationFAQs on bisphenol A in consumer products
FAQs on bisphenol A in consumer products Updated BfR FAQ, 19 February 2015 The substance bisphenol A is contained in polycarbonate products such as food and drink containers and bottles. Bisphenol A is
More informationSTUDIES TO EVALUATE THE SAFETY OF RESIDUES OF VETERINARY DRUGS IN HUMAN FOOD: GENERAL APPROACH TO ESTABLISH AN ACUTE REFERENCE DOSE
VICH GL54 (SAFETY) ARfD November 2016 For Implementation at Step 7 STUDIES TO EVALUATE THE SAFETY OF RESIDUES OF VETERINARY DRUGS IN HUMAN FOOD: GENERAL APPROACH TO ESTABLISH AN ACUTE REFERENCE DOSE (ARfD)
More informationPHTHALATES STAKEHOLDER WORKSHOP SUMMARY REPORT
PHTHALATES STAKEHOLDER WORKSHOP SUMMARY REPORT March 26, 2014 Ottawa, Canada Contents Acronyms... 3 INTRODUCTION... 4 Overview Phthalate Substances Grouping and the Chemicals Management Plan... 5 The Proposed
More informationAssessing and Managing Health Risks from Chemical Constituents and Contaminants of Food
16 17 September 2013 Assessing and Managing Health Risks from Chemical Constituents and Contaminants of Food Workshop on A Framework for Assessing the Health, Environmental and Social Effects of the Food
More informationChemical Name: Metolachlor ESA CAS: Synonyms: Ethanesulfonate degradate of metolachlor; CGA
2011 Health Risk Limits for Groundwater Health Risk Assessment Unit, Environmental Health Division 651-201-4899 651-201-5797 TDD Web Publication Date: March 21, 2011 Chemical Name: Metolachlor ESA CAS:
More informationMr. Bruce Allen. Dr. Harvey Clewell.
Mr. Bruce Allen. Mr. Allen has 27 years of experience related to human and environmental health and safety. He has expertise as a biomathematician involved in risk assessment, modeling, statistical analysis,
More informationApproaches to Integrating Evidence From Animal and Human Studies in Chemical Assessments
Approaches to Integrating Evidence From Animal and Human Studies in Chemical Assessments Kris Thayer, National Center for Environmental Assessment (NCEA) Integrated Risk Information System (IRIS) Division
More informationConsideration of Reproductive/Developmental Mode of Action Data from Laboratory Animals in the Risk Assessment of Environmental Chemicals
Consideration of Reproductive/Developmental Mode of Action Data from Laboratory Animals in the Risk Assessment of Environmental Chemicals Susan Makris U.S. EPA, National Center for Environmental Assessment
More informationAddendum to the 12th Report on Carcinogens
Addendum to the 12th Report on Carcinogens Published by the U.S. Department of Health and Human Services, National Toxicology Program The twelfth edition of the National Toxicology Program (NTP) Report
More informationPresenting Uncertainty in the Context of Toxicological, Biological Monitoring and Exposure Information. William H.
Presenting Uncertainty in the Context of Toxicological, Biological Monitoring and Exposure Information William H. Farland, PhD, ATS Presenting Risk Information and Uncertainty Concerns regarding how uncertainty
More informationECPA position paper on the criteria for the determination of endocrine disrupting properties under Regulation
POSITION PAPER 09/06/2016 PP/14/PD/23734 ECPA position paper on the criteria for the determination of endocrine disrupting properties under Regulation The European Commission is currently developing new
More informationFirst Phase of Impact Assessment on Endocrine Disruptors:
First Phase of Impact Assessment on Endocrine Disruptors: How to screen which chemicals would fall under different options for criteria to identify endocrine disruptors EU Conference on Endocrine Disruptors,
More informationof the French Agency for Food, Environmental and Occupational Health & Safety
The Director General Maisons-Alfort, 27 March 2012 of the French Agency for Food, Environmental and Occupational Health & Safety regarding a request for scientific and technical support for the revising
More informationDevelopment of NJ Human Health-based Criteria and Standards
Development of NJ Human Health-based Criteria and Standards Gloria Post NJDEP Office of Science Presented to: Public Health Standing Committee October 18, 2010 Human Health-based Criteria and Standards
More informationCHAPTER 7 TOXICITY ASSESSMENT
CHAPTER 7 TOXICITY ASSESSMENT The purpose of the toxicity assessment is to assessment, the amount of new toxicological weigh available evidence regarding the potential evaluation of primary data required
More informationThe ABC's of EDCs: Endocrine Disrupting Chemicals in the Environment
The ABC's of EDCs: Endocrine Disrupting Chemicals in the Environment David Quanrud Water Resources Research Center 2007 Water Conference Phoenix, Arizona June 5, 2007 What is an endocrine disrupting compound?
More information10/18/2016. Endocrine Disruption and the Environment. Endocrine Policy Forum US EPA S LEGISLATIVE MANDATES (1996)
Endocrine Disruption and the Environment Ellen Mihaich, Ph.D., DABT PCPC Environmental Safety Workshop October 25, 2016 1 Endocrine Policy Forum Consortium of List 1 test order recipients and other interested/involved
More informationDose Response Approaches for Nuclear Receptor Mediated Modes of Action Workshop Preliminary Report
Dose Response Approaches for Nuclear Receptor Mediated Modes of Action Workshop Preliminary Report Workshop Organizing Committee 2 Major Goals of the Workshop Determine whether the biology of nuclear receptors
More informationendocrine disruptors?
worry about endocrine disruptors? Endocrine active substances are chemicals that can interfere with the body s hormone system and may have the potential to cause harm. They are used in everyday objects
More informationQuantitative Risk Assessment: An Overview and Discussion of Emerging Issues. Anne-Marie Nicol, PhD
Quantitative Risk Assessment: An Overview and Discussion of Emerging Issues Anne-Marie Nicol, PhD Today s talk Broader overview of Risk Assessment process (at the US EPA) Explanation of the 4 step formal
More informationFINAL. Recommendations for Update to Arsenic Soil CTL Computation. Methodology Focus Group. Contaminated Soils Forum. Prepared by:
A stakeholder body advising the Florida Department of Environmental Protection FINAL Recommendations for Update to Arsenic Soil CTL Computation Prepared by: Methodology Focus Group Contaminated Soils Forum
More informationCase Study Summary: Appendix: Evaluation of Hazard Range for Three Additional Chemicals: Tetrachloroethylene, Chromium (VI) and Arsenic.
Case Study Summary: Practical Guidance on the Development of a Non-cancer Hazard Range for Effective Risk Assessment and Risk Management of Contaminated Sites: A Case Study with Trichloroethylene and Other
More informationHexavalent Chromium Oral Reference Dose
Development Support Document Proposed, June Hexavalent Chromium Oral Reference Dose CAS Registry Number: 0-- Prepared by Joseph T. Haney, Jr., M.S. Toxicology Division Office of the Executive Director
More informationChemical Name: Metolachlor OXA CAS: Synonyms: Oxanilic acid degradate of metolachlor
2011 Health Risk Limits for Groundwater Health Risk Assessment Unit, Environmental Health Division 651-201-4899 651-201-5797 TDD Web Publication Date: March 21, 2011 Chemical Name: Metolachlor OXA CAS:
More informationRethinking Approaches To Low Dose Extrapolation for Environmental Health Risk Assessment
Rethinking Approaches To Low Dose Extrapolation for Environmental Health Risk Assessment Introduction Over the past half-century, methods for quantitatively assessing the human health risks from exposures
More informationAPPLICATION FOR AUTHORISATION: ESTABLISHING REFERENCE DNELS FOR BBP
Helsinki, 2 September 20 RAC/26/20/07 Rev. (Agreed at RAC-26) APPLICATION FOR AUTHORISATION: ESTABLISHING REFERENCE DNELS FOR BBP Background At the 22 nd meeting of the Committee for Risk Assessment (RAC)
More informationAGREEMENT OF THE MEMBER STATE COMMITTEE ON THE IDENTIFICATION OF 4,4'-ISOPROPYLIDENEDIPHENOL (BISPHENOL A) AS A SUBSTANCE OF VERY HIGH CONCERN
AGREEMENT OF THE MEMBER STATE COMMITTEE ON THE IDENTIFICATION OF 4,4'-ISOPROPYLIDENEDIPHENOL (BISPHENOL A) AS A SUBSTANCE OF VERY HIGH CONCERN According to Articles 57 and 59 of Regulation (EC) 1907/2006
More informationISRTP Workshop. Cumulative Risk for Endocrine Disrupters: The Case FOR a dose addition approach. Andreas Kortenkamp
ISRTP Workshop Cumulative Risk for Endocrine Disrupters: The Case FOR a dose addition approach Andreas Kortenkamp The School of Pharmacy, University of London 19-20 February 2008 Endocrine disruption:
More informationRobert G. Sussman, Ph.D., DABT Managing Principal, Eastern Operations. SafeBridge Consultants, Inc. Mountain View, CA New York, NY Liverpool, UK
Robert G. Sussman, Ph.D., DABT Managing Principal, Eastern Operations SafeBridge Consultants, Inc. Mountain View, CA New York, NY Liverpool, UK Paracelsus (1493 1541) All substances are poisons; there
More informationLow Dose Effects and Non-monotonic Dose Responses for Endocrine Active Chemicals: Science to Practice Workshop
Low Dose Effects and Non-monotonic Dose Responses for Endocrine Active Chemicals: Science to Practice Workshop Agenda Tuesday, September 11 Thursday, September 13, 2012 Charité Medical University of Berlin,
More informationComments from PlasticsEurope
Polycarbonate/Bisphenol A Group Follow-up Meeting on the Web-Based Public Consulting on Bisphenol A Brussels, April 23 2014 Comments from PlasticsEurope Dieter Beyer Representing the Polycarbonate/Bisphenol
More informationData Package of the Peer Consultation Meeting on the Chloroacetanilide Degradates. May 11 th 12 th, Northern Kentucky University, METS Center
Data Package of the Peer Consultation Meeting on the Chloroacetanilide Degradates May 11 th 12 th, 2009 Northern Kentucky University, METS Center 1 (This page intentionally left blank.) 2 Table of Contents
More informationEndocrine Disruption and Human Health Effects
Endocrine Disruption and Human Health Effects Aldert H. Piersma Center for Health Protection RIVM Bilthoven-NL 1 NVvA Kurhaus 14 April 2016 Silent Spring (1962) Environmental effects of pesticides, particularly
More informationStrategies for health interpretation: development of HBM healthbased guidance values for individual phthalates and BPA
Strategies for health interpretation: development of HBM healthbased guidance values for individual phthalates and BPA Workshop on policy uptake of HBM-results Brussels - Nov 2018 Eva Ougier (ANSES) &
More informationPoly-fluoroalkyl substances (PFASs), also called perfluoroalkyl substances (PFASs)
Poly-fluoroalkyl substances (PFASs), also called perfluoroalkyl substances (PFASs) Perfluorooctane sulphonic acid (PFOS), and perfluorooctanoic acid (PFOA) belong to a group of man-made compounds called
More informationHEALTH CONSULTATION. Tom Lea Park EL PASO COUNTY METAL SURVEY EL PASO, EL PASO COUNTY, TEXAS EPA FACILITY ID: TX
HEALTH CONSULTATION Tom Lea Park EL PASO COUNTY METAL SURVEY EL PASO, EL PASO COUNTY, TEXAS EPA FACILITY ID: TX0000605388 September 6, 2002 Prepared by: The Texas Department of Health Under a Cooperative
More informationA Japanese View on Assessment of Endocrine Disrupting Chemicals
A Japanese View on Assessment of Endocrine Disrupting Chemicals Hiroaki Aoyama, Ph.D. Executive Director, Toxicology Division Institute of Environmental Toxicology Food Safety Committee of Japan (FSCJ)
More informationTopic 3.13 Use of NOAEL, benchmark dose, and other models for human risk assessment of hormonally active substances*,
Pure Appl. Chem., Vol. 75, Nos. 11 12, pp. 2151 2158, 2003. 2003 IUPAC Topic 3.13 Use of NOAEL, benchmark dose, and other models for human risk assessment of hormonally active substances*, R. Woodrow Setzer,
More informationSAICM/OEWG.2/INF/19. Note by the secretariat. Distr.: General 25 November 2014 English only
Distr.: General 25 November 2014 English only Open-ended Working Group of the International Conference on Chemicals Management Second meeting Geneva, 15 17 December 2014 Item 5 (a) (v) of the provisional
More informationIntroduction. Dietary Exposure Assessment Tools for Prioritizing Food Safety Concerns. Workshop on. Stephen S. Olin
Introduction Workshop on Dietary Exposure Assessment Tools for Prioritizing Food Safety Concerns Stephen S. Olin International Life Sciences Institute Research Foundation Issues Ensuring a safe and wholesome
More informationReport of a Workshop on Dose-Response Approaches for Nuclear Receptor- Mediated Modes of Action
Report of a Workshop on Dose-Response Approaches for Nuclear Receptor- Mediated Modes of Action The 2010 Society of Risk Analysis Meeting Salt Lake City, Utah Robert Budinsky The Dow Chemical Company Outline
More informationEndocrine Disrupting Chemicals: New considerations in the toxics space TURI Annual Meeting
Endocrine Disrupting Chemicals: New considerations in the toxics space TURI Annual Meeting Laura N. Vandenberg, PhD UMass Amherst School of Public Health April 25, 2018 Disclosure statement I am funded
More informationRisk Characterization
Risk Characterization 1 Learning Objectives By the end of this module, participants should have an understanding of: The purpose of risk characterization Integrating the results of hazard identification,
More informationGuidelines of the Scientific Committee on Food for the development of tolerable upper intake levels for vitamins and minerals
EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL Directorate C - Scientific Opinions C3 - Management of scientific committees II; scientific co-operation and networks Scientific Committee
More informationWhat are the challenges in addressing adjustments for data uncertainty?
What are the challenges in addressing adjustments for data uncertainty? Hildegard Przyrembel, Berlin Federal Institute for Risk Assessment (BfR), Berlin (retired) Scientific Panel for Dietetic Foods, Nutrition
More informationEFSA working group on BPA assessment protocol. Ursula Gundert-Remy Chair of the EFSA Working Group BPA assessment Protocol
EFSA working group on BPA assessment protocol Ursula Gundert-Remy Chair of the EFSA Working Group BPA assessment Protocol Workshop on BPA hazard assessment protocol Brussels, 14 September 2017 Acknowledgements
More informationCOMMISSION REGULATION (EU) / of XXX
EUROPEAN COMMISSION Brussels, XXX SANTE/11992/2017 Rev. 0 [ ](2017) XXX draft COMMISSION REGULATION (EU) / of XXX amending Annex II to Regulation (EC) No 1107/2009 by setting out scientific criteria for
More informationMethodologies for development of human health criteria and values for the lake Erie drainage basin.
3745-1-42 Methodologies for development of human health criteria and values for the lake Erie drainage basin. [Comment: For dates of non-regulatory government publications, publications of recognized organizations
More informationScientific Challenges in the Risk Assessment of Food Contact Materials 2017 Workshop of the Food Packaging Forum Foundation
Scientific Challenges in the Risk Assessment of Food Contact Materials 2017 Workshop of the Food Packaging Forum Foundation Zürich, October 5, 2017 www.foodpackagingforum.org Welcome FPF s mandate Donations
More informationEndocrine disruptors and effects on reproduction DEMETER: a support tool for occupational risks assessment
Endocrine disruptors and effects on reproduction DEMETER: a support tool for occupational risks assessment ISSA Symposium 1 June 2016 Stéphane Malard Medical Studies and Assistance Division, INRS, Paris
More informationCIR Precedents COSMETIC INGREDIENT REVIEW. Endocrine Activity 9/2017
COSMETIC INGREDIENT REVIEW CIR Precedents Endocrine Activity 9/2017 This document is a compilation of issues discussed by the CIR Expert Panel along with precedent language used in CIR Reports to articulate
More informationOutline: risk assessment. What kind of environmental risks do we commonly consider? 11/19/2013. Why do we need chemical risk assessment?
Outline: Human health h and ecological l risk assessment Purpose of risk assessment Methodology for quantifying risk Case study: Children s exposure to As from CCA wood staircases Issues practical and
More informationLow-doseresponse. toxicology and risk assessment
17 Efsa Scientific Colloquium Summary Report ISSN 1830-4737 Low-doseresponse in toxicology and risk assessment 14 15 June 2012, Parma, Italy EFSA Scientific Colloquium Summary Report 17 Low-dose-response
More informationHolistic Approach to Human Risk Assessments the Current Approach Fit for Purpose?
Holistic Approach to Human Risk Assessments the Current Approach Fit for Purpose? EFSA Scientific Conference 2018 Susanne Hougaard Bennekou Senior Advisor, The Danish EPA Parma, 19th. September 2018 Disclaimer
More informationChemical food safety in the U.S. analysis of FDA s scientific basis for assessing chemical risk. Tom Neltner October 9, 2014
Chemical food safety in the U.S. analysis of FDA s scientific basis for assessing chemical risk Tom Neltner October 9, 2014 Topics 1. Current focus of U.S. public interest community 2. Comparison of U.S.
More informationPerchlorate Comments for Science Advisory Board (SAB) Perchlorate Panel
Government Affairs Office 1300 Eye Street NW Suite 701W Washington, DC 20005-3314 T 202.628.8303 F 202.628.2846 The Authoritative Resource on Safe Water SM July 10, 2012 Advocacy Communications Conferences
More informationPremarket Review. FFDCA Section 201(s) FFDCA Section 201(s) (cont.)
FFDCA Section 201(s) intended use of which results or may reasonably be expected to result, directly or indirectly, in its becoming a component or otherwise affecting the characteristics of any food Mitchell
More informationThe Scientific Rationale for Deriving Database and Toxicodynamic Uncertainty Factors for Reproductive or Developmental Toxicants
1 2 3 4 6 7 The Scientific Rationale for Deriving Database and Toxicodynamic Uncertainty Factors for Reproductive or Developmental Toxicants 8 9 1 11 12 13 Prepared by Bernard Gadagbui Jay Zhao Andy Maier
More informationScience Policy Notice
Science Policy Notice SPN2002-01 Children s Health Priorities within the Pest Management Regulatory Agency (publié aussi en français) January 3, 2002 This document is published by the Submission Coordination
More informationDRAFT COMMISSION DELEGATED REGULATION (EU) /... of XXX
EUROPEAN COMMISSION Brussels, XXX C(2016) 3752 projet DRAFT COMMISSION DELEGATED REGULATION (EU) /... of XXX setting out scientific criteria for the determination of endocrine-disrupting properties pursuant
More informationAssessment and regulation of endocrine disrupters under European chemical legislations Susy Brescia Chemicals Regulation Directorate (CRD) HSE
Health and and Safety Executive Assessment and regulation of endocrine disrupters under European chemical legislations Susy Brescia Chemicals Regulation Directorate (CRD) HSE EDs and the current EU legislative
More informationAppendix B Expert Interviews
Appendix B Expert Interviews The following experts were contacted and asked to answer a questionnaire on the development of amphibian metamorphosis assays to detect endocrine disrupting chemicals that
More information1, 2, 3-Trichloropropane (TCP): Assessment of Risks from Drinking Water
1, 2, 3-Trichloropropane (TCP): Assessment of Risks from Drinking Water 1, 2, 3-Trichloropropane (TCP): Assessment of Risks from Drinking Water Prepared for Alaimo Group (Engineers and Architects) 200
More informationPart 2. Chemical and physical aspects
Part 2. Chemical and physical aspects 12. Chemical and physical aspects: introduction 12.1 Background information used The assessment of the toxicity of drinking-water contaminants has been made on the
More information- draft scientific opinion -
The Re-evaluation of faspartame - draft scientific opinion - Dr. Alicja Mortensen Chair of EFSA s ANS Panel Follow-up meeting on the web-based public consultation on aspartame 9 April 2013, Bruxelles Draft
More informationCHAPTER 2: RISK ANALYSIS
Update Project Chapter : Risk Analysis Draft May 00 0 0 0 0 0 PRINCIPLES AND METHODS FOR THE RISK ASSESSMENT OF CHEMICALS IN FOOD CHAPTER : RISK ANALYSIS Contents CHAPTER : RISK ANALYSIS.... INTRODUCTION....
More informationAn In Vitro Alternative For Predicting Systemic Toxicity. By: James McKim, Ph.D., DABT Chief Science Officer
An In Vitro Alternative For Predicting Systemic Toxicity By: James McKim, Ph.D., DABT Chief Science Officer What is Systemic Toxicity and What do We Want From Alternative Methods? Toxicity that occurs
More informationChallenges of MoA/HRF under CLH
Challenges of MoA/HRF under CLH Marja Pronk (RAC member) MoA/HRF Workshop, 4 November 2014 CLP Regulation on MoA Part 1. General principles for C&L 1.1.1 Expert judgement & weight of evidence determination
More informationpresents Introduction to Toxicology and its Role in Green Chemistry
presents Introduction to Toxicology and its Role in Green Chemistry August 6, 2013 12:00 PM 1:00 PM ET Disclaimer: The Michigan Green Chemistry Clearinghouse (MGCC) is committed to providing webinars that
More informationpesticides in the EU regulatory framework Prof Andreas Kortenkamp
Addressing combined effects of pesticides in the EU regulatory framework Prof Andreas Kortenkamp Brunel University London Info session on cumulative risk assessment for o sess o o cu u at e s assess e
More informationEXCERPT FROM MERCURY STUDY REPORT TO CONGRESS VOLUME I: EXECUTIVE SUMMARY
EXCERPT FROM MERCURY STUDY REPORT TO CONGRESS VOLUME I: EXECUTIVE SUMMARY December 1997 Office of Air Quality Planning and Standards and Office of Research and Development U.S. Environmental Protection
More informationReview of Danish EPA List of EDCs
Review of Danish EPA List of EDCs February 2017 For many years, Denmark has been very active on the endocrine issue. In 2011 the Danish EPA proposed a set of criteria for the EU Commission to use to identify
More informationSpecial Review Decision: Imazapyr
Re-evaluation Note REV2016-02 Special Review Decision: Imazapyr (publié aussi en français) 7 January 2016 This document is published by the Health Canada Pest Management Regulatory Agency. For further
More informationEOH3101 PRINCIPLES OF ENVIRONMENTAL HEALTH ENVIRONMENTAL HEALTH ISSUES: ENVIROMENTAL HORMONES
EOH3101 PRINCIPLES OF ENVIRONMENTAL HEALTH ENVIRONMENTAL HEALTH ISSUES: ENVIROMENTAL HORMONES INTRODUCTION Endocrine disruptors are chemicals that may interfere with the body s endocrine system and produce
More informationCHARACTERIZING THE IMPACTS OF UNCERTAINTY AND SCIENTIFIC JUDGMENT IN EXPOSURE LIMIT DEVELOPMENT
CHARACTERIZING THE IMPACTS OF UNCERTAINTY AND SCIENTIFIC JUDGMENT IN EXPOSURE LIMIT DEVELOPMENT Andrew Maier, Ph.D., CIH, DABT TERA Robert Sussman, Ph.D., DABT SafeBridge Consultants, Inc. Bruce Naumann,
More informationHuman Health Risk Assessment Overview [For the APS/OPP Roundtable]
Human Health Risk Assessment Overview [For the APS/OPP Roundtable] Christina Swartz, USEPA Nov. 12, 2008 [Slides Courtesy of Mike Metzger, USEPA] The Risk Assessment Paradigm: The Red Book Hazard Identification
More informationConsiderations in Toxicology Study Design and Interpretation: An Overview Gradient Corporation: Lewis, AS; Beyer, LA; Langlois, CJ; Yu, CJ; Wait, AD
Considerations in Toxicology Study Design and Interpretation: An Overview Gradient Corporation: Lewis, AS; Beyer, LA; Langlois, CJ; Yu, CJ; Wait, AD Introduction The use of animal data to evaluate the
More informationSAB Report to the Board of the Glass Packaging Institute
SAB Report to the Board of the Glass Packaging Institute A Brief Overview of Significant Studies on BPA During 2013 November, 2013 Glass is ENDLESSLY Recyclable Introduction Number and diversity of studies
More informationDioxins and dioxin-like compounds (DLCs) are released into the environment from
July 2006 Public Summary Health Risks from Dioxin and Related Compounds Evaluation of the EPA Reassessment Dioxins and dioxin-like compounds (DLCs) are released into the environment from several sources,
More informationAre tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
Regulatory Toxicology and Pharmacology 41 (2005) 128 133 Regulatory Toxicology and Pharmacology www.elsevier.com/locate/yrtph Are tumor incidence rates from chronic bioassays telling us what we need to
More information